Cargando…

Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer

BACKGROUND: Colorectal cancer liver metastases (CRLM) has not been identified as a unified disease entity due to the differences in the severity of metastatic disease and tumor aggressiveness. A screen for specific prognostic risk subgroups is urgently needed. The current study aimed to investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jianhong, Li, Weihao, Fan, Wenhua, Zhang, Rongxin, Li, Xinyue, Xiao, Binyi, Dong, Yuejin, Wan, Desen, Pan, Zhizhong, Lin, Junzhong, Wu, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542290/
https://www.ncbi.nlm.nih.gov/pubmed/34688293
http://dx.doi.org/10.1186/s12935-021-02250-x
_version_ 1784589399919427584
author Peng, Jianhong
Li, Weihao
Fan, Wenhua
Zhang, Rongxin
Li, Xinyue
Xiao, Binyi
Dong, Yuejin
Wan, Desen
Pan, Zhizhong
Lin, Junzhong
Wu, Xiaojun
author_facet Peng, Jianhong
Li, Weihao
Fan, Wenhua
Zhang, Rongxin
Li, Xinyue
Xiao, Binyi
Dong, Yuejin
Wan, Desen
Pan, Zhizhong
Lin, Junzhong
Wu, Xiaojun
author_sort Peng, Jianhong
collection PubMed
description BACKGROUND: Colorectal cancer liver metastases (CRLM) has not been identified as a unified disease entity due to the differences in the severity of metastatic disease and tumor aggressiveness. A screen for specific prognostic risk subgroups is urgently needed. The current study aimed to investigate the prognostic value of DNA ploidy, stroma fraction and nucleotyping of initially resectable liver metastases from patients with CRLM. METHODS: One hundred thirty-nine consecutive patients with initially resectable CRLM who underwent curative liver resection from 2006 to 2018 at Sun Yat-sen University Cancer Center were selected for analysis. DNA ploidy, stroma fraction and nucleotyping of liver metastases were evaluated using automated digital imaging systems. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox regression models. RESULTS: DNA ploidy was identified as an independent prognostic factor for RFS (HR, 2.082; 95% CI 1.053–4.115; P = 0.035) in the multivariate analysis, while stroma-tumor fraction and nucleotyping were not significant prognostic factors. A significant difference in 3-year RFS was observed among the low-, moderate- and high-risk groups stratified by a novel parameter combined with the tumor burden score (TBS) and DNA ploidy (72.5% vs. 63.2% vs. 37.3%, P = 0.007). The high-risk group who received adjuvant chemotherapy had a significantly better 3-year RFS rate than those without adjuvant chemotherapy (46.7% vs. 24.8%; P = 0.034). CONCLUSIONS: Our study showed that DNA ploidy of liver metastases is an independent prognostic factor for patients with initially resectable CRLM after liver resection. The combination of DNA ploidy and TBS may help to stratify patients into different recurrence risk groups and may guide postoperative treatment among the patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02250-x.
format Online
Article
Text
id pubmed-8542290
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85422902021-10-25 Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer Peng, Jianhong Li, Weihao Fan, Wenhua Zhang, Rongxin Li, Xinyue Xiao, Binyi Dong, Yuejin Wan, Desen Pan, Zhizhong Lin, Junzhong Wu, Xiaojun Cancer Cell Int Primary Research BACKGROUND: Colorectal cancer liver metastases (CRLM) has not been identified as a unified disease entity due to the differences in the severity of metastatic disease and tumor aggressiveness. A screen for specific prognostic risk subgroups is urgently needed. The current study aimed to investigate the prognostic value of DNA ploidy, stroma fraction and nucleotyping of initially resectable liver metastases from patients with CRLM. METHODS: One hundred thirty-nine consecutive patients with initially resectable CRLM who underwent curative liver resection from 2006 to 2018 at Sun Yat-sen University Cancer Center were selected for analysis. DNA ploidy, stroma fraction and nucleotyping of liver metastases were evaluated using automated digital imaging systems. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and Cox regression models. RESULTS: DNA ploidy was identified as an independent prognostic factor for RFS (HR, 2.082; 95% CI 1.053–4.115; P = 0.035) in the multivariate analysis, while stroma-tumor fraction and nucleotyping were not significant prognostic factors. A significant difference in 3-year RFS was observed among the low-, moderate- and high-risk groups stratified by a novel parameter combined with the tumor burden score (TBS) and DNA ploidy (72.5% vs. 63.2% vs. 37.3%, P = 0.007). The high-risk group who received adjuvant chemotherapy had a significantly better 3-year RFS rate than those without adjuvant chemotherapy (46.7% vs. 24.8%; P = 0.034). CONCLUSIONS: Our study showed that DNA ploidy of liver metastases is an independent prognostic factor for patients with initially resectable CRLM after liver resection. The combination of DNA ploidy and TBS may help to stratify patients into different recurrence risk groups and may guide postoperative treatment among the patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02250-x. BioMed Central 2021-10-23 /pmc/articles/PMC8542290/ /pubmed/34688293 http://dx.doi.org/10.1186/s12935-021-02250-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Peng, Jianhong
Li, Weihao
Fan, Wenhua
Zhang, Rongxin
Li, Xinyue
Xiao, Binyi
Dong, Yuejin
Wan, Desen
Pan, Zhizhong
Lin, Junzhong
Wu, Xiaojun
Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer
title Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer
title_full Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer
title_fullStr Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer
title_full_unstemmed Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer
title_short Prognostic value of a novel biomarker combining DNA ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer
title_sort prognostic value of a novel biomarker combining dna ploidy and tumor burden score for initially resectable liver metastases from patients with colorectal cancer
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8542290/
https://www.ncbi.nlm.nih.gov/pubmed/34688293
http://dx.doi.org/10.1186/s12935-021-02250-x
work_keys_str_mv AT pengjianhong prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT liweihao prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT fanwenhua prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT zhangrongxin prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT lixinyue prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT xiaobinyi prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT dongyuejin prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT wandesen prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT panzhizhong prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT linjunzhong prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer
AT wuxiaojun prognosticvalueofanovelbiomarkercombiningdnaploidyandtumorburdenscoreforinitiallyresectablelivermetastasesfrompatientswithcolorectalcancer